Evaluation of platelet-rich fibrin matrix combined with PGE-1 injection on erectile function in patients with refractory response to PDE5-I: a randomized placebo-controlled study
International Urology and Nephrology · 2024
DOI: 10.1007/s11255-024-04139-w ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Urology and Nephrology, 2024. Verfasst von Adham Zaazaa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Andrology, Sexology and STDs Kasr Al-Ainy, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt. Hauptthemen laut MEDLINE: Alprostadil, Erectile Dysfunction, Phosphodiesterase 5 Inhibitors, Penile Erection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: We studied the effect of a platelet-rich fibrin matrix (PRFM) combined with prostaglandin E-1 (PGE-1) injection on erectile function in patients refractory to response for phosphodiesterase type 5 inhibitors (PDE5-Is). METHODS: This randomized, double-blind, placebo-controlled study included 80 patients. The patients were randomly assigned to four groups and blinded together with the administrating physicians to the nature of the intracorporeal injection (ICI) therapies. Group (1) received saline, group (2) received platelet-rich fibrin matrix (PRFM), group (3) received prostaglandin E-1 (PGE-1), and group (4) received a combination of PRFM + PGE-1. The patients received ICI therapy weekly for 8 consecutive weeks. Clinical information and follow-up data were obtained at 1, 2, 3, and 6 months. RESULTS: A significant increase occurred in the validated Arabic version of the International Index of Erectile Function (ArIIEF-5) score in group (4) compared to the other three groups (p value = 0.037). There was a significant difference in erection hardness scale (EHS) scores among all groups after receiving the different treatments (p = 0.004). A significant increase was seen in the ArIIEF-5 score in groups 4 and 3 compared to that in groups 1 and 2 (p < 0.001). There was also a significant increase in the arterial dilatation % in groups 4 and 3 compared to that in groups 1 and 2 (p = 0.019). CONCLUSION: The combination of PRFM plus PGE-1 had shown significant improvement in the ArIIEF-5 score, yet the patients still had mild to moderate ED.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Andrology, Sexology and STDs Kasr Al-Ainy, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt.
- Department of Andrology, Sexology and STDs Kasr Al-Ainy, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt. samehfayek@kasralainy.edu.eg.
- Egypt Ministry of Health and Population, Cairo, Egypt.
Zitieren
APA
Zaazaa, A., Eid, M. A., GamalEl Din, S. F., Zeidan, A., Hakeem, A. A., Farag, M. A. F., Fawzy, A., & Kaddah, A. (2024). Evaluation of platelet-rich fibrin matrix combined with PGE-1 injection on erectile function in patients with refractory response to PDE5-I: a randomized placebo-controlled study. International Urology and Nephrology. https://doi.org/10.1007/s11255-024-04139-w
Vancouver
Zaazaa A, Eid MA, GamalEl Din SF, Zeidan A, Hakeem AA, Farag MAF, et al. Evaluation of platelet-rich fibrin matrix combined with PGE-1 injection on erectile function in patients with refractory response to PDE5-I: a randomized placebo-controlled study. International Urology and Nephrology. 2024. doi:10.1007/s11255-024-04139-w
BibTeX
@article{Zaazaa2024,
author = {Zaazaa, Adham and Eid, Mohamed Abbas and GamalEl Din, Sameh Fayek and Zeidan, Ashraf and Hakeem, Ahmed AbdEl and Farag, Mohamed Abdel Fattah and Fawzy, Ahmed and Kaddah, Amr},
title = {Evaluation of platelet-rich fibrin matrix combined with PGE-1 injection on erectile function in patients with refractory response to PDE5-I: a randomized placebo-controlled study},
journal = {International Urology and Nephrology},
year = {2024},
doi = {10.1007/s11255-024-04139-w}
}
EUVIMED